Biofrontera Past Earnings Performance

Past criteria checks 0/6

Biofrontera has been growing earnings at an average annual rate of 1.7%, while the Pharmaceuticals industry saw earnings growing at 12.5% annually. Revenues have been declining at an average rate of 1.5% per year.

Key information

1.7%

Earnings growth rate

4.3%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate-1.5%
Return on equity-14.4%
Net Margin-11.8%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Biofrontera makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:B8FK Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2422-3118
31 Mar 24300128
31 Dec 23320138
30 Sep 2329-9138
30 Jun 2328-11138
31 Mar 2325-20137
31 Dec 2226-44127
30 Sep 223211187
30 Jun 223110247
31 Mar 223015297
31 Dec 212938347
30 Sep 2128-16286
30 Jun 2127-16295
31 Mar 2129-12265
31 Dec 2030-13285
30 Sep 2033-17335
30 Jun 2033-22375
31 Mar 2031-10455
31 Dec 1931-7445
30 Sep 19261444
30 Jun 19268405
31 Mar 1923-8335
31 Dec 1821-9314
30 Sep 1819-14244
30 Jun 1816-15224
31 Mar 1814-16214
31 Dec 1712-16204
30 Sep 1711-18215
30 Jun 179-16175
31 Mar 178-14145
31 Dec 166-11125
30 Sep 164-994
30 Jun 164-784
31 Mar 164-976
31 Dec 154-1176
30 Sep 154-1277
30 Jun 153-1377
31 Mar 153-1075
31 Dec 143-1175
30 Sep 143-1074
30 Jun 143-1074
31 Mar 143-964
31 Dec 133-853

Quality Earnings: B8FK is currently unprofitable.

Growing Profit Margin: B8FK is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: B8FK is unprofitable, but has reduced losses over the past 5 years at a rate of 1.7% per year.

Accelerating Growth: Unable to compare B8FK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: B8FK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).


Return on Equity

High ROE: B8FK has a negative Return on Equity (-14.38%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies